Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2022-10-16 Management Reports
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Quarterly Investor Update – Q2 FY23 Test Volumes rise 36%
Management Reports Classification · 95% confidence The document is titled as an 'Investor Update' dated October 2022 and contains detailed operational and commercial progress information, including test volumes, sales and marketing efforts, clinical evidence updates, and regulatory developments related to Medicare coverage. It discusses quarterly performance metrics and strategic initiatives but does not present full financial statements or comprehensive financial performance data typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). The document is about 15,000 characters long, indicating it is substantive and not a brief announcement or a simple report publication notice. It is not a transcript, audit report, or legal filing. The content focuses on business updates, market progress, and regulatory environment affecting the company’s operations, which aligns with the nature of a Management Report or Management Discussion and Analysis (MDA). Therefore, the most appropriate classification is Management Reports (MDA).
2022-10-16 English
Letter to Shareholders 8 pages 1.2MB
Interim / Quarterly Report Classification · 85% confidence The document is a detailed shareholder update for the second quarter ending September 2022. It includes operational and commercial progress, test volume data, clinical evidence program updates, and commentary from the CEO. It references upcoming half-year financial results but does not contain actual financial statements or detailed financial analysis. The content focuses on business updates, market development, and strategic initiatives rather than formal financial reporting. The document length is substantial (15,000 characters), indicating it is more than a brief announcement. However, it lacks the comprehensive financial data and statutory disclosures typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is not a call transcript, audit report, or regulatory filing. Given the nature of the content as a shareholder update with operational and strategic information for a specific quarter, the best fit is an Interim / Quarterly Report (IR). Q2 2023
2022-10-16 English
Quarterly Investor Update - Q2 FY23 Test Volumes rise 36% 8 pages 1.2MB
Management Reports Classification · 95% confidence The document is a detailed shareholder update for the second quarter ending September 2022. It includes operational and commercial progress, test volume data, clinical evidence program updates, and commentary from the CEO. It references upcoming half-year financial results but does not contain actual financial statements or detailed financial analysis. The content focuses on business updates, market progress, and strategic initiatives rather than formal financial reporting. The document length is substantial (15,000 characters), indicating it is more than a brief announcement. However, it lacks the comprehensive financial data and analysis typical of an Interim/Quarterly Report (IR). It is not an earnings release (ER) since it does not present key financial highlights or earnings figures. It is not an investor presentation (IP) or annual report (10-K). The document is best classified as a Management Report (MDA) because it provides management's detailed explanation of business trends, operational progress, and outlook without full financial statements.
2022-10-16 English
Update on Te Whatu Ora Southern Commercial Agreement 1
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 22 September 2022 providing an update on a commercial agreement status with Te Whatu Ora – Southern. It discusses the contract status and business case approval process but contains no financial statements, regulatory certifications, voting results, or detailed financial data. The length is short (2260 characters) and it is an update on a commercial agreement rather than a financial report or regulatory filing. There is no indication of earnings release, management changes, or other specific report types. Therefore, it fits best as a general Regulatory Filing (RNS) as a miscellaneous company announcement that does not fit other categories.
2022-09-22 English
Update on Te Whatu Ora – Southern Commercial Agreement
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 22nd September 2022 from Pacific Edge regarding an update on a commercial agreement with Te Whatu Ora – Southern. It discusses the status of a contract and provides background information about the company and its product, Cxbladder. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management changes, no earnings data, and no legal proceedings mentioned. The document is relatively short (2260 characters) and serves as a business update or commercial agreement status announcement rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. Given the content and length, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-09-21 English
Pacific Edge Limited (“PEB”) – Trading Halt Lifted
Regulatory Filings Classification · 95% confidence The document is a short memorandum from NZX Limited regarding the lifting of a trading halt on Pacific Edge Limited's securities. It is an announcement about trading status and does not contain financial data, report content, or detailed disclosures. It is not a report, certification, or detailed filing but a regulatory announcement related to market operations. Given its nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.